Belinda S Lennerz1,2, Anna Barton3, Richard K Bernstein4, R David Dikeman5, Carrie Diulus6, Sarah Hallberg7, Erinn T Rhodes1, Cara B Ebbeling1,2, Eric C Westman8, William S Yancy8, David S Ludwig9,2. 1. Division of Endocrinology, and. 2. New Balance Foundation Obesity Prevention Center, Boston Children's Hospital and Harvard Medical School, Harvard University, Boston, Massachusetts. 3. Richmond Diabetes and Endocrinology, Bon Secours Medical Group, Richmond, Virginia. 4. New York Diabetes Center, Mamaroneck, New York. 5. Lockheed Martin, Honolulu, Hawaii. 6. Crystal Clinic Orthopaedic Center, Akron, Ohio. 7. Virta Health and Indiana University Health, School of Medicine, Indiana University, Indianapolis, Indiana; and. 8. Duke University Medical Center, Durham, North Carolina. 9. Division of Endocrinology, and david.ludwig@childrens.harvard.edu.
Abstract
OBJECTIVES: To evaluate glycemic control among children and adults with type 1 diabetes mellitus (T1DM) who consume a very low-carbohydrate diet (VLCD). METHODS: We conducted an online survey of an international social media group for people with T1DM who follow a VLCD. Respondents included adults and parents of children with T1DM. We assessed current hemoglobin A1c (HbA1c) (primary measure), change in HbA1c after the self-reported beginning of the VLCD, total daily insulin dose, and adverse events. We obtained confirmatory data from diabetes care providers and medical records. RESULTS: Of 316 respondents, 131 (42%) were parents of children with T1DM, and 57% were of female sex. Suggestive evidence of T1DM (based on a 3-tier scoring system in which researchers took into consideration age and weight at diagnosis, pancreatic autoimmunity, insulin requirement, and clinical presentation) was obtained for 273 (86%) respondents. The mean age at diagnosis was 16 ± 14 years, the duration of diabetes was 11 ± 13 years, and the time following a VLCD was 2.2 ± 3.9 years. Participants had a mean daily carbohydrate intake of 36 ± 15 g. Reported mean HbA1c was 5.67% ± 0.66%. Only 7 (2%) respondents reported diabetes-related hospitalizations in the past year, including 4 (1%) for ketoacidosis and 2 (1%) for hypoglycemia. CONCLUSIONS: Exceptional glycemic control of T1DM with low rates of adverse events was reported by a community of children and adults who consume a VLCD. The generalizability of these findings requires further studies, including high-quality randomized controlled trials.
OBJECTIVES: To evaluate glycemic control among children and adults with type 1 diabetes mellitus (T1DM) who consume a very low-carbohydrate diet (VLCD). METHODS: We conducted an online survey of an international social media group for people with T1DM who follow a VLCD. Respondents included adults and parents of children with T1DM. We assessed current hemoglobin A1c (HbA1c) (primary measure), change in HbA1c after the self-reported beginning of the VLCD, total daily insulin dose, and adverse events. We obtained confirmatory data from diabetes care providers and medical records. RESULTS: Of 316 respondents, 131 (42%) were parents of children with T1DM, and 57% were of female sex. Suggestive evidence of T1DM (based on a 3-tier scoring system in which researchers took into consideration age and weight at diagnosis, pancreatic autoimmunity, insulin requirement, and clinical presentation) was obtained for 273 (86%) respondents. The mean age at diagnosis was 16 ± 14 years, the duration of diabetes was 11 ± 13 years, and the time following a VLCD was 2.2 ± 3.9 years. Participants had a mean daily carbohydrate intake of 36 ± 15 g. Reported mean HbA1c was 5.67% ± 0.66%. Only 7 (2%) respondents reported diabetes-related hospitalizations in the past year, including 4 (1%) for ketoacidosis and 2 (1%) for hypoglycemia. CONCLUSIONS: Exceptional glycemic control of T1DM with low rates of adverse events was reported by a community of children and adults who consume a VLCD. The generalizability of these findings requires further studies, including high-quality randomized controlled trials.
Authors: Curt L Rohlfing; Hsiao-Mei Wiedmeyer; Randie R Little; Jack D England; Alethea Tennill; David E Goldstein Journal: Diabetes Care Date: 2002-02 Impact factor: 19.112
Authors: Antonio Ceriello; Markolf Hanefeld; Lawrence Leiter; Louis Monnier; Alan Moses; David Owens; Naoko Tajima; Jaakko Tuomilehto Journal: Arch Intern Med Date: 2004-10-25
Authors: Ruth S Weinstock; Dongyuan Xing; David M Maahs; Aaron Michels; Michael R Rickels; Anne L Peters; Richard M Bergenstal; Breanne Harris; Stephanie N Dubose; Kellee M Miller; Roy W Beck Journal: J Clin Endocrinol Metab Date: 2013-06-12 Impact factor: 5.958
Authors: Christopher D Morrison; Cristal M Hill; Marina A DuVall; Carolyn E Coulter; Jasmin L Gosey; Matthew J Herrera; Lauren E Maisano; Hunter X Sikaffy; David H McDougal Journal: J Diabetes Complications Date: 2020-02-08 Impact factor: 2.852
Authors: E D Alten; A Chaturvedi; M Cullimore; A A Fallon; L Habben; I Hughes; N T O'Malley; H Rahimi; D Renodin-Mead; B L Schmidt; G A Weinberg; D R Weber Journal: Osteoporos Int Date: 2020-01-04 Impact factor: 4.507
Authors: Belinda S Lennerz; Andrew P Koutnik; Svetlana Azova; Joseph I Wolfsdorf; David S Ludwig Journal: J Clin Invest Date: 2021-01-04 Impact factor: 14.808